531 related articles for article (PubMed ID: 34441008)
1. Microbiota and Probiotics: The Role of Limosilactobacillus Reuteri in Diverticulitis.
Piccioni A; Franza L; Vaccaro V; Saviano A; Zanza C; Candelli M; Covino M; Franceschi F; Ojetti V
Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441008
[TBL] [Abstract][Full Text] [Related]
2. The antimicrobial effect of
Ananda N; Suniarti DF; Bachtiar EW
F1000Res; 2023; 12():1495. PubMed ID: 38434653
[TBL] [Abstract][Full Text] [Related]
3. Limosilactobacillus reuteri ameliorates preeclampsia in mice via improving gut dysbiosis and endothelial dysfunction.
Li B; Shi Y; Qiu W; Lin Q; Zeng S; Hou Y; Zhou H; Chen M; Zhang D
Biomed Pharmacother; 2023 May; 161():114429. PubMed ID: 36841030
[TBL] [Abstract][Full Text] [Related]
4. Lactobacillus Reuteri DSM 17938
Saviano A; Brigida M; Migneco A; Gunawardena G; Zanza C; Candelli M; Franceschi F; Ojetti V
Medicina (Kaunas); 2021 Jun; 57(7):. PubMed ID: 34201542
[No Abstract] [Full Text] [Related]
5. Lactobacillus reuteri derived from horse alleviates Escherichia coli-induced diarrhea by modulating gut microbiota.
Wang D; Zeng J; Wujin C; Ullah Q; Su Z
Microb Pathog; 2024 Mar; 188():106541. PubMed ID: 38224920
[TBL] [Abstract][Full Text] [Related]
6.
Peng Y; Ma Y; Luo Z; Jiang Y; Xu Z; Yu R
Front Cell Infect Microbiol; 2023; 13():1254198. PubMed ID: 37662007
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the anti-inflammatory Lactobacillus reuteri BM36301 and its probiotic benefits on aged mice.
Lee J; Yang W; Hostetler A; Schultz N; Suckow MA; Stewart KL; Kim DD; Kim HS
BMC Microbiol; 2016 Apr; 16():69. PubMed ID: 27095067
[TBL] [Abstract][Full Text] [Related]
8. Gut Microbiota and Acute Diverticulitis: Role of Probiotics in Management of This Delicate Pathophysiological Balance.
Piccioni A; Franza L; Brigida M; Zanza C; Torelli E; Petrucci M; Nicolò R; Covino M; Candelli M; Saviano A; Ojetti V; Franceschi F
J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33919818
[TBL] [Abstract][Full Text] [Related]
9. Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study.
del Campo R; Garriga M; Pérez-Aragón A; Guallarte P; Lamas A; Máiz L; Bayón C; Roy G; Cantón R; Zamora J; Baquero F; Suárez L
J Cyst Fibros; 2014 Dec; 13(6):716-22. PubMed ID: 24636808
[TBL] [Abstract][Full Text] [Related]
10. Identification of soybean peptides and their effect on the growth and metabolism of Limosilactobacillus reuteri LR08.
Zhang C; Xia S; Zhang Y; Zhu S; Li H; Liu X
Food Chem; 2022 Feb; 369():130923. PubMed ID: 34455331
[TBL] [Abstract][Full Text] [Related]
11. Limosilactobacillus reuteri SLZX19-12 Protects the Colon from Infection by Enhancing Stability of the Gut Microbiota and Barrier Integrity and Reducing Inflammation.
Wu J; Lin Z; Wang X; Zhao Y; Zhao J; Liu H; Johnston LJ; Lu L; Ma X
Microbiol Spectr; 2022 Jun; 10(3):e0212421. PubMed ID: 35658572
[TBL] [Abstract][Full Text] [Related]
12. The Effects of Limosilactobacillus reuteri LR-99 Supplementation on Body Mass Index, Social Communication, Fine Motor Function, and Gut Microbiome Composition in Individuals with Prader-Willi Syndrome: a Randomized Double-Blinded Placebo-Controlled Trial.
Kong XJ; Liu K; Zhuang P; Tian R; Liu S; Clairmont C; Lin X; Sherman H; Zhu J; Wang Y; Fong M; Li A; Wang BK; Wang J; Yu Z; Shen C; Cui X; Cao H; Du T; Wan G; Cao X
Probiotics Antimicrob Proteins; 2021 Dec; 13(6):1508-1520. PubMed ID: 34115318
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulation of dendritic cells by Lactobacillus reuteri surface components and metabolites.
Engevik MA; Ruan W; Esparza M; Fultz R; Shi Z; Engevik KA; Engevik AC; Ihekweazu FD; Visuthranukul C; Venable S; Schady DA; Versalovic J
Physiol Rep; 2021 Jan; 9(2):e14719. PubMed ID: 33463911
[TBL] [Abstract][Full Text] [Related]
14. Effect of Oral Probiotic
Yang S; Reid G; Challis JRG; Gloor GB; Asztalos E; Money D; Seney S; Bocking AD
Nutrients; 2020 Jan; 12(2):. PubMed ID: 32019222
[TBL] [Abstract][Full Text] [Related]
15. Use of
Dargenio VN; Cristofori F; Dargenio C; Giordano P; Indrio F; Celano G; Francavilla R
Benef Microbes; 2022 Aug; 13(3):221-242. PubMed ID: 35212258
[TBL] [Abstract][Full Text] [Related]
16. Oral Microbiota Shift after 12-Week Supplementation with Lactobacillus reuteri DSM 17938 and PTA 5289; A Randomized Control Trial.
Romani Vestman N; Chen T; Lif Holgerson P; Öhman C; Johansson I
PLoS One; 2015; 10(5):e0125812. PubMed ID: 25946126
[TBL] [Abstract][Full Text] [Related]
17.
Hu MX; He F; Guo YX; Mo LZ; Zhu X
J Agric Food Chem; 2022 Sep; 70(38):11935-11943. PubMed ID: 36111836
[TBL] [Abstract][Full Text] [Related]
18.
Koppinger MP; Lopez-Pier MA; Skaria R; Harris PR; Konhilas JP
Am J Physiol Heart Circ Physiol; 2020 Jul; 319(1):H32-H41. PubMed ID: 32412785
[TBL] [Abstract][Full Text] [Related]
19. Randomized control trial on the efficacy of Limosilactobacillus reuteri ATCC PTA 4659 in reducing inflammatory markers in acute uncomplicated diverticulitis.
Ojetti V; Saviano A; Brigida M; Petruzziello C; Caronna M; Gayani G; Franceschi F
Eur J Gastroenterol Hepatol; 2022 May; 34(5):496-502. PubMed ID: 35045564
[TBL] [Abstract][Full Text] [Related]
20. Secretion of Recombinant Interleukin-22 by Engineered Lactobacillus reuteri Reduces Fatty Liver Disease in a Mouse Model of Diet-Induced Obesity.
Oh JH; Schueler KL; Stapleton DS; Alexander LM; Yen CE; Keller MP; Attie AD; van Pijkeren JP
mSphere; 2020 Jun; 5(3):. PubMed ID: 32581074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
